Genprex, Inc. Common Stock (GNPX) Stock Price

GNPXStock
$2.11−99.60%52W
Market Cap$1.73M
P/E—
PEG Ratio—
Div yield—
Beta-0.94

GNPX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-101.98%
Price vs S&P 500 (4W)-38.04%
VGM Score4.47

GNPX Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q1 2025-$451.00-$286.00+36.59%(+$165.00)
Q3 2024-$3003.00-$1353.00+54.95%(+$1650.00)
Q2 2024-$2530.00-$3300.00-30.43%(-$770.00)

GNPX Analyst Recommendations

Jun 2025
Jul 2025
Aug 2025
Oct 2025
4.14
4.14
4.14
4.14

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
GNPXGenprex, Inc. Common Stock
——F————$2.11
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Genprex, Inc. Common Stock

Genprex Inc develops non-viral gene therapies for cancer and diabetes. The company's Oncoprex Delivery System uses lipid nanoparticles to deliver therapeutic genes, with its lead candidate Reqorsa under evaluation in three clinical trials for non-small cell and small cell lung cancer.